68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer

Schmidkonz, Christian; Cordes, Michael; Schmidt, Daniela; Bäuerle, Tobias; Goetz, Theresa Ida; Beck, Michael; Prante, Olaf; Cavallaro, Alexander; Uder, Michael; Wullich, Bernd; Goebell, Peter J.; Kuwert, Torsten; Ritt, Philipp

doi:10.1007/s00259-018-4042-z

Cited by 98 publications

(174 citation statements)

References 32 publications

Supporting

Mentioning

156

Contrasting

Unclassified

Order By: Relevance

“…Therefore, a semiautomatic method would pave the way toward a whole-body tumor load quantification in prostate cancer patients. In the present study, the mean analyzed PSMA-TV and PSMA-TL were 823 mL and 7,273, respectively, indicating that our patient cohort was much more advanced than previous reports in the literature using manual segmentation (24,25). Furthermore, this factor could also explain why we obtained stronger correlations between serum PSA and PSMA ligand PET-derived parameters than those previously described in 2 reports (24,25).…”

Section: Discussionsupporting

confidence: 50%

See 1 more Smart Citation

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸Ga-PSMA11 PET/CT

et al. 2019

View full text Add to dashboard Cite

Our aim was to introduce and validate qPSMA, a semiautomatic software package for whole-body tumor burden assessment in prostate cancer patients using 68 Ga-prostate-specific membrane antigen (PSMA) 11 PET/CT. Methods: qPSMA reads hybrid PET/ CT images in DICOM format. Its pipeline was written using Python and C11 languages. A bone mask based on CT and a normaluptake mask including organs with physiologic 68 Ga-PSMA11 uptake are automatically computed. An SUV threshold of 3 and a liver-based threshold are used to segment bone and soft-tissue lesions, respectively. Manual corrections can be applied using different tools. Multiple output parameters are computed, that is, PSMA ligand-positive tumor volume (PSMA-TV), PSMA ligand-positive total lesion (PSMA-TL), PSMA SUV mean , and PSMA SUV max . Twenty 68 Ga-PSMA11 PET/CT data sets were used to validate and evaluate the performance characteristics of qPSMA. Four analyses were performed: validation of the semiautomatic algorithm for liver background activity determination, assessment of intra-and interobserver variability, validation of data from qPSMA by comparison with Syngo.via, and assessment of computational time and comparison of PSMA PET-derived parameters with serum prostate-specific antigen. Results: Automatic liver background calculation resulted in a mean relative difference of 0.74% (intraclass correlation coefficient [ICC], 0.996; 95%CI, 0.989;0.998) compared with METAVOL. Intraand interobserver variability analyses showed high agreement (all ICCs . 0.990). Quantitative output parameters were compared for 68 lesions. Paired t testing showed no significant differences between the values obtained with the 2 software packages. The ICC estimates obtained for PSMA-TV, PSMA-TL, SUV mean , and SUV max were 1.000 (95%CI, 1.000;1.000), 1.000 (95%CI, 1.000;1.000), 0.995 (95%CI, 0.992;0.997), and 0.999 (95%CI, 0.999;1.000), respectively. The first and second reads for intraobserver variability resulted in mean computational times of 13.63 min (range, 8.22-25.45 min) and 9.27 min (range, 8.10-12.15 min), respectively (P 5 0.001). Highly significant correlations were found between serum prostate-specific antigen value and both PSMA-TV (r 5 0.72, P , 0.001) and PSMA-TL (r 5 0.66, P 5 0.002). Conclusion: Semiautomatic analyses of whole-body tumor burden in 68 Ga-PSMA11 PET/CT is feasible. qPSMA is a robust software package that can help physicians quantify tumor load in heavily metastasized prostate cancer patients.

show abstract

Section: Discussionsupporting

confidence: 50%

“…This resulted in a relatively low mean PSMA-TV and PSMA-TL of 3.4 mL and 33.2 per patient, respectively. Schmidkonz et al (25) extended the work by analyzing patients with a higher tumor burden (PSMA-TV and PSMA-TL of 7.4 mL and 73.8, respectively). No segmentation time was reported in either work.…”

Section: Discussionmentioning

confidence: 99%

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸Ga-PSMA11 PET/CT

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Studies done by Ceci et al [9] and Caroli et al [10] correlation in patients with mCRPC compared to 33% using RECIST 1.1 [11]. Other molecular imaging studies making use of [68Ga]PSMA-11 PET/CT for the assessment of therapy response in patients with metastatic prostate cancer have reported similar findings of significant correlation between response to chemotherapy and PET parameters [23,22].…”

Section: Discusssionmentioning

confidence: 80%

WITHDRAWN: Exploratory Study of [18F]fluciclovine PET/CT for Response Assessment to Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Akintayo

Bilen

Abiodun-Ojo

et al. 2020

Preprint

View full text Add to dashboard Cite

Background The ability to accurately monitor response to treatment in patients with metastatic castration resistant prostate cancer (mCRPC) on chemotherapy has been a challenge. Conventional methods of therapy response assessment have limitations and molecular imaging has been explored as an important alternative. We set out t o determine if anti-1-amino-3-anti-1-amino-3-[18F]-fluorocyclobutane-1-carboxylic acid ([18F]fluciclovine) positron emission tomography/computed tomography (PET/CT) changes reflect response to docetaxel chemotherapy in mCRPC. Results Seven patients with mCRPC were enrolled. Each patient was scheduled to have [18F]fluciclovine PET/CT at baseline, and after 1 and 6 cycles of chemotherapy. Uptake parameters were recorded in the prostate/bed and up to 10 metastatic lesions. Decrease in uptake of ≥30% was considered response (R); appearance of new lesions or >30% increase in uptake was progressive disease (PD); and change of < 30% uptake was stable disease (SD). Prostate specific antigen (PSA) was obtained at baseline and before each cycle. Bone scintigraphy and CT were acquired at baseline and after the 6th cycle. Assessment of response was based on Prostate Cancer Clinical Trial Working Group 3 recommendations. Correlation between [18F]fluciclovine uptake and time to PSA progression was also determined. All patients completed the 1 st and 2 nd [18F]fluciclovine PET/CT, while 4/7 patients completed all 3 scans. PET response correlated with PSA response in 3/7 (42.9%) patients and 3/4 (75%) patients after 1 and 6 cycles of docetaxel, respectively. Bone scan and CT correlated with PSA response in 1/4 (25%) patients. Mean SUVmax and SUVmean were significantly higher in patients with progressive disease versus non-progressive disease after 6 cycles of docetaxel (p<0.05), but not at baseline or after 1 cycle of docetaxel. There was non-significant correlation of changes in [18F]fluciclovine uptake with changes in PSA after 1 and 6 cycles of docetaxel. There was no significant correlation between PET parameters and time to PSA progression. Conclusion [18F]fluciclovine PET/CT has better correlation than CT or bone scan with PSA response for patients with mCRPC treated with docetaxel. [18F]fluciclovine PET/CT did not predict time to PSA progression. Larger studies exploring the utility of [18F]fluciclovine PET for response assessment are recommended.

show abstract

“…Schmidkonz ve ark. 'nın bildirdiği oldukça yeni bir çalışmada, biyokimyasal rekürrensi olan toplam 142 PK'li hastaya Ga-68 PSMA-11 ile PET/BT uygulanmıştır (38). Görüntü alanına giren 641 PSMA pozitif lezyon için kantitatif değerlendirme ile tüm vücut PSMA tümör hacmi (PSMA-TV) ve tüm vücut TL-PSMA yanı sıra SUV maks ve SUV ort değerleri ölçülmüştür.…”

Section: Sistemik Tedavi Yanıtını Değerlendirmede Ga-68psmapet/btunclassified

Possible Role of Ga-68 PSMA PET/CT in Evaluation of Systemic Treatment Response in Patients with Metastatic Prostate Cancer

Sivrikoz¹

2018

nts

View full text Add to dashboard Cite

68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer

Cited by 98 publications

References 32 publications

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸Ga-PSMA11 PET/CT

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸Ga-PSMA11 PET/CT

WITHDRAWN: Exploratory Study of [18F]fluciclovine PET/CT for Response Assessment to Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Possible Role of Ga-68 PSMA PET/CT in Evaluation of Systemic Treatment Response in Patients with Metastatic Prostate Cancer

Contact Info

Product

Resources

About

68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer

Cited by 98 publications

References 32 publications

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using 68Ga-PSMA11 PET/CT

WITHDRAWN: Exploratory Study of [18F]fluciclovine PET/CT for Response Assessment to Docetaxel in Patients with Metastatic Castration Resistant Prostate Cancer

Possible Role of Ga-68 PSMA PET/CT in Evaluation of Systemic Treatment Response in Patients with Metastatic Prostate Cancer

Contact Info

Product

Resources

About

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸Ga-PSMA11 PET/CT

qPSMA: Semiautomatic Software for Whole-Body Tumor Burden Assessment in Prostate Cancer Using ⁶⁸Ga-PSMA11 PET/CT